Sangamo up on FDA's 'fast track' tag for genetic disorder therapy
22/05/2023 13:25
** Drug developer Sangamo Therapeutics Inc's shares SGMO.O
up 5.4% at $1.4 before the bell
** U.S. FDA grants "fast track" designation to co's
experimental gene therapy, ST-920, for treating fabry disease
** Fabry disease is a rare genetic disorder; symptoms
include pain in hands and feet
** "Fast track" tag facilitates development and expedites
review of drug candidates intended to treat serious conditions
** ST-920 is currently being evaluated in an
early-to-mid-stage study for safety and tolerability, with a
total of 20 patients dosed to date
** As of last close, SGMO stock down 58.92% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))